Gilead Forms Kidney Disease Pact with Goldfinch Bio
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)
Published: 14 May-2019
DOI: 10.3833/pdr.v2019.i5.2423 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to strengthen its pipeline, Gilead has agreed to a multi-year collaboration with Goldfinch Bio to discover, develop and commercialise a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases using Goldfinch’s genetic and biologic platforms...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS